Aurobindo Integrates Apotex And Prepares For Sandoz
Firm Says Nothing ‘Extraneous’ Holding Up FTC Nod For Sandoz Deal
Executive Summary
Aurobindo believes it has “substantially addressed” all requirements for an FTC go-ahead for its acquisition of Sandoz’s US dermatology and generic oral solids businesses. The integration of the acquired Apotex business in Europe is also shaping up.
You may also be interested in...
FDA Gives Then Rescinds Clearance For Aurobindo Plant
Aurobindo Pharma shares have nosedived after the US Food and Drug Administration said an investigation into one of the Indian drugmaker’s plants was still open, days after issuing a notice giving the site the all-clear.
Deal Watch: Molecular Templates Aligns With Vertex On Optimizing Stem Cell Candidates
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.
Aurobindo Hits Back Over Sandoz Delay Rumors
Aurobindo has hit back over rumors that completion of its pending transaction to acquire Sandoz’ US dermatology and oral-solids businesses has been delayed until next year over FTC information requests.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: